Navigation Links
Halting Avandia Use Hikes Blood Sugar Levels
Date:4/16/2009

Study found diabetics who discontinued drug had less treatment, worse management of disease

THURSDAY, April 16 (HealthDay News) -- Many patients who stopped using the diabetes drug rosiglitazone (Avandia) due to concerns about the drug's safety received less treatment and developed higher blood glucose levels, U.S. researchers report.

An analysis of scientific evidence released in 2007 found that rosiglitazone increased the risk of cardiovascular disease and heart attack, which led many doctors and patients to discontinue use of the drug.

Of the diabetes patients in this new study, 89 percent were using combination therapy before discontinuing use of rosiglitazone. After discontinuation, 33 percent of patients were on combination therapy. Another 13 percent of patients weren't prescribed any diabetes medications.

The blood sugar control of patients was also affected after they stopped taking the drug, said Dr. Etta Fanning, of the University of Texas Health Science Center, and colleagues.

"In patients who received combination therapy, and who had laboratory values in both pre- and post-discontinuation periods, significant increases were observed in both fasting blood glucose and A1c," the authors said in a news release from the journal Endocrine Practice, which published the study.

This study reaffirms that patients who discontinue use of rosiglitazone and another thiazolidinedione (TZD) called pioglitazone (Actos) are at increased risk for higher fasting blood glucose and hemoglobin A1c levels, which may increase their cardiovascular risk, cardiologists Dr. Stuart Zarich of Yale Medical School and Dr. Richard Nesto of the Lahey Clinic, wrote in an accompanying journal editorial.

More information

The National Diabetes Education Program has more about diabetes control.



-- Robert Preidt



SOURCE: Endocrine Practice, news release, April 14, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Especially Among Children, Prevention is Key to Halting Obesity Epidemic, President of American Dietetic Association Tells Congressional Subcommittee
2. Diabetes Drug Avandia Boosts Heart Risks: Study
3. GSK Revises US Labeling for Avandia(R)
4. Avandia Label to Get Heart-Attack Warning
5. Diabetes Drug Avandia Could Weaken Bones
6. Safety Concerns Prompt Prime to Remove Avandia(R) from Formulary
7. Older Diabetics Using Avandia Face Increased Death Risk
8. Avandia May Slow Atherosclerosis After Bypass Surgery
9. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
10. LegalView Re-Launches its Avandia Information Portal with News of the Type 2 Diabetes Drug's Risks and Dangers
11. Consumer Group Seeks FDA Ban on Avandia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Halting Avandia Use Hikes Blood Sugar Levels
(Date:8/19/2017)... ... August 19, 2017 , ... Parker at Stonegate, ... over 1,000 passionate employees, caregivers, volunteers, thought leaders, researchers, educators and partners leading ... it was time to refresh the carpeting with the goal of maintaining the ...
(Date:8/18/2017)... , ... ... ... For Immediate Release                Contact: ... Shows Young Women Seek Sex and Relationship Advice from their ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... liquid handling handheld devices. Through an educational webinar, they will present the line ... a chance to learn how easy you can automate everyday pipetting tasks. , ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning assistance that serves communities throughout southern Florida, is working to ... provide scholarship assets to children from low income families. , The Take Stock ...
(Date:8/18/2017)... Raton, Fl (PRWEB) , ... August 18, 2017 ... ... largest network of highly trained practitioners specializing in bioidentical hormone replacement therapy and ... associated with hormone imbalance and conditions of aging, such as menopause, andropause, thyroid ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)... Aug. 8, 2017   ... diluted (GAAP) loss per share from continuing operations ... revenues increased 16 percent to $110 million ... 27 percent to $161 million ... from continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
Breaking Medicine Technology: